Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Table 1

Baseline characteristics of the included studies.

Authors, year [ref.]	Total	Population	Mean BMI category	Dose n-3/day	Duration	Control	Component n-3/1000 mg capsule	Diagosis
Argo et al., 2015 [27]	34	NASH	Obese	3000 mg	12 months	Placebo	35% EPA + 250% DHA + 10% other n-3s	Liver biopsy + haematochemical
Scorletti et al., 2014 [28]	103	NAFLD	Obese	4000 mg	15–18 months	Placebo	46% EPA + 38% DHA	Liver biopsy or imaging evidence or features of MetS
Sanyal et al., 2014 [29]	119	NASH/NAFLD	Obese	2700 mg	12 months	Placebo	Highly purified EPA ethyl ester	Liver biopsy + haematochemical
Sofi et al., 2010 [30]	11	NAFLD	Obese	830 mg	12 months	Placebo	56.6% EPA + 28.9% DHA	Ultrasonography + haematochemical
Dasarathy et al., 2015 [31]	37	NASH with diabetes	Obese	3600 mg	12 months	without treatment	60% EPA + 40% DHA	Liver biopsy + haematochemical
Zhu et al., 2008 [2]	134	NAFLD	Obese	2000 mg	24 weeks	Placebo	Seal oils	Ultrasonography + haematochemical
Spadaro et al., 2008 [32]	36	NAFLD	Obese	2000 mg	6 months	Without treatment	Not mentioned	Ultrasonography + haematochemical
Capanni et al., 2006 [33]	56	NAFLD	Obese	1000 mg	12 months	Placebo	37.5% EPA + 62.5% DHA	Ultrasonography + haematochemical
Vega et al., 2008 [34]	16	Subset of DHS cohort	Obese	9000 mg	8 wk	Placebo	51.4% C20:5, 23.9% C22:6	Elevated HTGC (MRS) + average ALT within reference range
Chen et al. 2008 [35]	46	NAFLD	Not specified	5000 mg	24 wk	Placebo	Harp seal oil capsules (not specified)	Elevated LFTs and TGs